Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell carcinoma

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 1, 2007, Pages 5-16

  Chouhan, Jyoti D ^a   Zamarripa, Daniel E ^a   Lai, Phillip H ^a   Oramasionwu, Christine U ^a   Grabinski, Jodi L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Metastatic renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

AG 013726; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CLARITHROMYCIN; COLONY STIMULATING FACTOR RECEPTOR; CYTOKINE; DRUG METABOLITE; ERYTHROMYCIN; HYPERICUM PERFORATUM EXTRACT; INTERLEUKIN 2; ITRACONAZOLE; KETOCONAZOLE; LENALIDOMIDE; M 200; NEFAZODONE; NEW DRUG; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SORAFENIB; SU 12662; SUNITINIB; THALIDOMIDE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING DISORDER; CANCER INHIBITION; CAPILLARY LEAK SYNDROME; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; CREATININE BLOOD LEVEL; DEPIGMENTATION; DERMATITIS; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; ERYTHEMA; FATIGUE; FLUID RETENTION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG EDEMA; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BLOOD VESSEL; SKIN DISCOLORATION; SKIN EDEMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VOMITING; DRUG EFFECT; KIDNEY TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES;

EID: 34250156738     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207077924     Document Type: Article

References (37)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006.
2. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Eng J Med. 2005; 353: 2477-90.
4. Pasche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA 2006; 295: 2537-38.
5. Proleukin® Package Insert. Chiron Corporation, 2000.
6. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Onc 2003; 21: 3127-32.
7. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Eng J Med 1998; 338: 1272-78.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Eng J Med 2007; 356: 115-24.
9. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment?. J Clin Onc 2006; 17: 2039-43.
10. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Onc 2005; 23: 133-41.
11. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Onc 1993; 11: 661-70.
12. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Onc 2006; 24: 5584-92.
13. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356:125-34.
14. Sutent® Package Insert. Pfizer, 2006.
15. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Onc 2006; 24: 16-24.
16. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth-factor targeted therapy in renal cell carcinoma. J Clin Onc 2005; 23: 1028-43.
17. Park S, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1α (HIF-1α): role of cytoplasmic trapping of HIF-2α. Cell Mol Biol 2003; 23: 4959-71.
18. Nathan P, Chao D, Brock C, Savage P, Harries M, Gore M, Eisen T. The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer 2006; 94: 1217-20.
19. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.
20. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, Pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Onc 2006; 24: 25-35.
21. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase 1 study in health subjects. Anticancer Drugs 2006; 17: 353-58.
22. Mendel DB, Laird AD, Xin X, Louie SG, Christenson JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
23. Fiedler W, Serve H, Dohner H, Schwittay, Ottmann OG, O'Farrell A, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-93.
24. Washington C, Eli M, Bello C, Schaaf L, Polasek E, Tan LH, et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. Proc Amer Soc Clin Onc 2003; 22 (abstract 553).
25. Bello C, Houk B, Sherman I, Misbah S, Sarapa N, Smeraglia J, et al. Effect on rifampin on the pharmacokinetics of SU11248 in healthy volunteers. Proc Amer Soc Clin Onc 2005; 23:16S (abstract 3078).
26. Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proc Amer Soc Cin Onc 2006; 24:18S (abstract 4522).
27. Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemec C, Garcia J, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Proc Amer Soc Clin Onc 2006; 24: 18S (abstract 4597).
28. Phase III randomized study of adjuvant sunitinib malate versus sorafenib in patients with resected renal cell carcinoma. ClinicalTrials.gov Identifier NCT00326898. clinicaltrials.gov. Accessed 19 June 2006.
29. Study of SU011248 given in a continuous daily regimen in patients with advanced renal cell cancer. ClinicalTrials.gov Identifier NCT00137423. clinicaltrials.gov. Accessed 19 June 2006.
30. A randomized phase III study of the efficacy and safety of sunitinib malate alone or in combination with interferon alfa-2b as first-line therapy for metastatic renal cell cancer (Renal EFFECT Trial). ClinicalTrials.gov Identifier NCT00267748. clinicaltrials.gov. Accessed 19 June 2006.
31. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, et al. for the National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology, v.2.2007. National Comprehensive Cancer Network Web Site. Retrieved 4 February 2007 at http://www.nccn.org/professionals/physician_gls/PDf/kidney.pdf.
32. Shaheen PE, Rini BI, Bukowski RM. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer 2006; 5: 78-81.
33. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism. in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
34. Ratain MJ, Eisen T, Stadler MW, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Onc 2006; 24: 2505-12.
35. Fleming T, ed. 2006 Redbook. Thomson PDR, Montvale (NJ), 2006.
36. Nexavar® Package Insert. Bayer Pharmaceutical Corporation, 2005.
37. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews. 2004, Issue 3. Art. No.: CD001425. DOI: 10.1002/14651858.CD001425.pub2.